Abstract
the administration of a potent acid inhibitor effectively prevented peptic ulcer (OR: 0.12, 95%CI: 0.06-0.25, p<0.01) regardless of LDA usage. In LDA users with the SLCO1B1 TT genotype, the risk of peptic ulcer tended to be high (ulcer [+] vs. ulcer [-] = 87.5% vs. 68.8%, p=0.06). For those with the UGT1A6 and CYP2C92, however, the risk wasn't increased. The peptic ulcer risk of SLCO1B1 TT genotype was also significantly higher than that of C allele carriers (C/T and C/C genotypes) in LDA users (OR: 3.18, 95%CI: 1.049.74, p=0.04). In Addition, the risk of peptic ulcer in patients with the TT genotype without a potent acid inhibitor tended to be higher than risk in C allele carriers (OR: 5.08, 95% CI: 0.89-28.96, p=0.06). Conclusions: We demonstrated that the TT genotype of SLCO1B1 increased the risk of peptic ulcer induced by LDA usage. Prophylactic use of acid inhibitors might therefore be an effective personalized treatment for preventing of gastricmucosal injury.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
